300 related articles for article (PubMed ID: 31393591)
1. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).
Salmanton-García J; Seidel D; Koehler P; Mellinghoff SC; Herbrecht R; Klimko N; Ráčil Z; Falces-Romero I; Ingram P; Benítez-Peñuela MÁ; Rodríguez JY; Desoubeaux G; Barać A; García-Vidal C; Hoenigl M; Mehta SR; Cheng MP; Klyasova G; Heinz WJ; Iqbal N; Krause R; Ostermann H; Penack O; Schalk E; Sheppard DC; Willinger B; Wisplinghoff H; Vehreschild JJ; Cornely OA; Vehreschild MJGT;
J Antimicrob Chemother; 2019 Nov; 74(11):3315-3327. PubMed ID: 31393591
[TBL] [Abstract][Full Text] [Related]
2. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
[TBL] [Abstract][Full Text] [Related]
3. Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016.
Heimann SM; Vehreschild MJGT; Cornely OA; Heinz WJ; Grüner B; Silling G; Kessel J; Seidel D; Vehreschild JJ
J Hosp Infect; 2019 Mar; 101(3):339-346. PubMed ID: 30423409
[TBL] [Abstract][Full Text] [Related]
4. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
5. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.
Pagano L; Cornely OA; Busca A; Caira M; Cesaro S; Gasbarrino C; Girmenia C; Heinz WJ; Herbrecht R; Lass-Flörl C; Nosari A; Potenza L; Racil Z; Rickerts V; Sheppard DC; Simon A; Ullmann AJ; Valentini CG; Vehreschild JJ; Candoni A; Vehreschild MJ
Haematologica; 2013 Oct; 98(10):e127-30. PubMed ID: 23716556
[No Abstract] [Full Text] [Related]
6. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
7. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis.
Lanternier F; Poiree S; Elie C; Garcia-Hermoso D; Bakouboula P; Sitbon K; Herbrecht R; Wolff M; Ribaud P; Lortholary O;
J Antimicrob Chemother; 2015 Nov; 70(11):3116-23. PubMed ID: 26316385
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
9. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
Kim JH; Benefield RJ; Ditolla K
Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
[TBL] [Abstract][Full Text] [Related]
10. Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.
Mezhir JJ; Mullane KM; Zarling J; Satoskar R; Pai RK; Roggin KK
Surg Infect (Larchmt); 2009 Oct; 10(5):447-51. PubMed ID: 19485785
[TBL] [Abstract][Full Text] [Related]
11. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
Heimann SM; Penack O; Heinz WJ; Rachow T; Egerer G; Kessel J; Claßen AY; Vehreschild JJ
Int J Infect Dis; 2019 Jun; 83():130-138. PubMed ID: 30978465
[TBL] [Abstract][Full Text] [Related]
12. [Pulmonary mucormycosis: report of 5 cases and review of 46 cases reported in China].
Yang YM; Fang BM; Xu XM; Fang F; Pan MM; Zhong XF; Sun TY
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):572-6. PubMed ID: 24252732
[TBL] [Abstract][Full Text] [Related]
13. Invasive mucormycosis in children with cancer: A retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association.
Muggeo P; Calore E; Decembrino N; Frenos S; De Leonardis F; Colombini A; Petruzziello F; Perruccio K; Berger M; Burnelli R; Zanazzo GA; Santoro N; Cesaro S
Mycoses; 2019 Feb; 62(2):165-170. PubMed ID: 30338581
[TBL] [Abstract][Full Text] [Related]
14. Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy.
Abboud CS; Bergamasco MD; Baía CE; Lallée MP; Zan AS; Zamorano MM; Pereira OI; Mies S
Transplant Proc; 2012 Oct; 44(8):2501-2. PubMed ID: 23026630
[TBL] [Abstract][Full Text] [Related]
15. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports.
Jeong W; Keighley C; Wolfe R; Lee WL; Slavin MA; Chen SC; Kong DCM
Int J Antimicrob Agents; 2019 May; 53(5):589-597. PubMed ID: 30639526
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study.
Cavassin FB; Magri MMC; Vidal JE; de Moraes Costa Carlesse FA; Falci DR; Baú-Carneiro JL; Breda GL; de Araújo Motta F; de Miranda Godoy CS; de Bastos Ascenço Soares R; De Oliveira CS; Mendes AVA; Morales HP; Montes PS; Taborda M; Rego CM; Félix MA; Katopodis PP; da Silva do Ó JR; Abrão MPL; Pereira TTT; Queiroz-Telles F
Clin Ther; 2024 Apr; 46(4):322-337. PubMed ID: 38403508
[TBL] [Abstract][Full Text] [Related]
18. Part 2: mucormycosis: focus on therapy.
Lynch JP; Zhanel GG
Expert Rev Anti Infect Ther; 2023; 21(7):737-748. PubMed ID: 37300820
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.
Luo G; Gebremariam T; Lee H; French SW; Wiederhold NP; Patterson TF; Filler SG; Ibrahim AS
Antimicrob Agents Chemother; 2013 Jul; 57(7):3340-7. PubMed ID: 23650163
[TBL] [Abstract][Full Text] [Related]
20. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
